Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for paclitaxel-induced peripheral neuropathy in breast cancer
IRCT20250809066797N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Neuropathy severity by NCI-CTCAE v5.0, Neuropathy severity by Peripheral Neuropathy Questionnaire and 2 more. Started Sep 2025; status: completed.
02
Drugs
metformin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20250809066797N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250809066797N1.